Evvy Deepens Its Commitment to Menopause Care with Precision Treatments for Midlife Vaginal Health

With Nearly One in Five Members in Peri/Menopause, Evvy Launches Prescription Vaginal Estrogen For Personalized Care

NEW YORK--(BUSINESS WIRE)--Evvy, the vaginal microbiome company pioneering biomarker-driven women’s healthcare, today announced the launch of a new Estradiol Vaginal Cream — uniquely formulated without parabens or sulfates. The Estradiol Vaginal Cream is offered alongside Evvy’s Vaginal Health Test and Clinical Care platform, enabling a first-of-its-kind, personalized, and holistic approach to vaginal changes in menopause. Together, the test and treatments enable personalized insights and ongoing care grounded in the latest vaginal microbiome science. This launch expands Evvy’s growing suite of menopause-focused Rx solutions, including its Soothing Vulva Cream and hormone-free Hyaluronic Acid Suppositories.

Up to 84% of women experience vaginal and urinary symptoms during menopause, yet these changes remain some of the least effectively treated in healthcare. That’s because vaginal estrogen impacts two deeply connected systems: the health of the vaginal tissue and the balance of the vaginal microbiome. Most menopause solutions focus only on replenishing tissue moisture, overlooking how shifts in bacteria and pH can drive irritation, infection, and discomfort. Evvy takes a holistic approach to support both tissue and microbial health, helping menopausal women finally get care that treats the root cause, not just the symptoms.

“With this launch, we’re bringing precision medicine to one of the most overlooked phases of women’s health,” said Priyanka Jain, Co-Founder and CEO of Evvy. “By integrating hormone care with vaginal microbiome insights, we can finally address the root causes of menopausal discomfort—not just the symptoms.”

Most generic estradiol creams prescribed today contain parabens, sulfates, and other irritants that are known to disrupt the vaginal microbiome. Evvy’s new compounded formula, created by the scientific team behind the world’s leading vaginal microbiome test, is free from parabens, sulfates, and unnecessary additives.

• Pure, Prescription-Grade Relief: Compounded in a 503a NABP-accredited pharmacy, with no parabens, sulfates, or unnecessary additives
• Holistic, Integrated Care: Delivered through Evvy’s precision health platform, the program combines pure, low-dose vaginal estrogen with advanced vaginal microbiome testing and personalized care. By addressing both tissue health and microbial balance, Evvy takes a truly comprehensive approach to vaginal symptoms in menopause.
• Accessible, At-Home Support: From testing to treatment to ongoing guidance, Evvy makes care for vaginal health in menopause seamless, affordable, and completely at home—so women can access evidence-based relief without stigma or inconvenience.

“Vaginal estrogen is one of the most effective – and underused – tools for restoring comfort after menopause,” said Dr. Kate McLean, OB-GYN and Chief Medical Officer at Evvy. “What makes Evvy’s formulation different is its commitment to an estrogen option with no parabens and sulfates — delivering the same effective relief from dryness and discomfort, without the unnecessary additives found in most generics.”

This launch further solidifies Evvy’s mission to transform overlooked female biomarkers into precision care pathways across every stage of life. Since 2021, Evvy has pioneered the world’s first CLIA-certified at-home vaginal microbiome test, built the largest real-world dataset on the vaginal microbiome, and scaled a care platform that integrates testing, personalized prescriptions, and 1:1 coaching. With menopause representing one of the most significant gaps in women’s health, the Estradiol Vaginal Cream signals a natural and strategic expansion for Evvy and its patients.

The Estradiol Vaginal Cream is now available nationwide at www.evvy.com.

About Evvy:

Founded in 2021, Evvy is closing the gender health gap by leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company offers the world’s first Vaginal Microbiome Test powered by metagenomic sequencing, analyzing over 700 microbes with a single, at-home swab — including those related to bacterial vaginosis, yeast infections, fertility outcomes, and more. Evvy’s care platform also includes precision treatment pathways from licensed clinicians and 1:1 health coaching. Through their test and care platform, Evvy has built the world’s largest dataset on the vaginal microbiome, and they are leveraging this novel data to improve outcomes across women’s health.